Sorrento Adds ADC Development Capabilities With Concortis Buyout

The San Diego biotech hopes to develop antibody-drug conjugate therapies for cancer that will offer more specific targeting and more stable drug-to-antibody ratios, compared to ADCs now on the market. The acquisition is just the latest in a busy stretch of deal-making for Sorrento.

Antibody-discovery play Sorrento Therapeutics Inc. capped off a busy stretch of recent deal-making Nov. 14 by announcing the purchase of privately held Concortis BioSystems Corp. for roughly $12 million in a stock transaction. The deal between two San Diego-based biotechs brings Sorrento the toxins and linking technologies needed to incorporate its proprietary G-MAB antibodies into antibody-drug conjugate (ADC) products for cancer.

Under the agreement, Sorrento will issue 1.3 million shares of stock to Concortis shareholders to close the deal. Shares of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

US FDA Staff Stability Should Be A Congressional Priority, Former Chief Of Staff Says

 

Lawmakers should address FDA staff upheaval and help the agency “get back on track,” former agency Chief of Staff Elizabeth Jungman said, while CBER Director Vinay Prasad told staff he is asking ex-colleagues to return to the agency.

US FDA ‘Commissioner’s Voucher’ As Public Relations Tool

 

NRx Pharma is trying to capitalize on the headlines about a new US FDA hyper-fast review program, illustrating that the lack of details in the FDA’s announcement is an opening for sponsors to try to grab some attention.

HHS Wants Employees (And Public?) To Report Diversity, Equity And Inclusion Discrimination

 
• By 

A survey asks FDA staff to disclose whether DEI policies caused discrimination or resulted in disciplinary action against career employees over the past five years, but uses a web form that the general public also can access.

US FDA Pediatric Adcomm To Examine HPV, Flu, Dengue Vaccines: No News Is Good News?

 
• By 

Pediatric Advisory Committee will weigh the FDA's recommendation that routine safety monitoring continue for Merck & Co's Gardasil and Sanofi's Fluzone and Dengvaxia despite a political climate that has been unkind to vaccines.

More from North America